Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis.
Minerva Biotechnologies has raised $4.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2023.
Minerva Biotechnologies is headquartered in Waltham, United States.
Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis.
Minerva Biotechnologies is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Minerva Biotechnologies — Funding & Investors." VCBacked, December 5, 2023, https://www.vcbacked.co/company/minerva-biotechnologies. Accessed August 14, 2026.
VCBacked. (2023). Minerva Biotechnologies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/minerva-biotechnologies
{{cite web |title=Minerva Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/minerva-biotechnologies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated